drugset / Trial / NCT06769152
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2026-12-31
- Completion
- 2027-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 3 mg/kg | Intravenous |